SAN DIEGO–(BUSINESS WIRE)–Invivoscribe®, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced that commercial shipments of the PrepQuant™ System have begun in North America. First unveiled at the American Association for Cancer Research Annual Meeting in April 2026, PrepQuant is now being delivered to customers, marking the platform’s progression from development and validation into commercial deployment. The commercial milestone extends Invi
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
